Application 761064

Type
BLA
Sponsor
GENENTECH INC

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761064Rituxan Hycelarituximab and hyaluronidase human351(a)Rx2026-07-01

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001RITUXAN HYCELARITUXIMAB; HYALURONIDASE (HUMAN RECOMBINANT)SOLUTION;SUBCUTANEOUS1400MG and 23400UNITS/11.7MLNoNo
002RITUXAN HYCELARITUXIMAB; HYALURONIDASE (HUMAN RECOMBINANT)SOLUTION;SUBCUTANEOUS1600MG and 26800UNITS/13.4MLNoNo

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Rituxan HycelaRITUXIMAB AND HYALURONIDASEGenentech, Inc.3e5b7e82-f018-4eaf-ae78-d6145a906b202025-12-15Boxed warning, Warnings, Adverse reactionsExact identifier
application number: BLA761064
ndc (product): 50242-109
ndc (product): 50242-108

NDC Listings For This Application#

NDC listings for this application page 1 of 1 · 20 matching rows.

NDC, Name, Nonproprietary name table
NDCNameNonproprietary nameLabelerMarketing categoryStatus
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-108Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent
50242-109Rituxan Hycelarituximab and hyaluronidaseGenentech, Inc.BLACurrent

Documents#

Document, Submission type, Date table
DocumentSubmission typeDate
67777SUPPL2021-06-14
67771SUPPL2021-06-11
67770SUPPL2021-06-11
62841SUPPL2020-05-06
62840SUPPL2020-05-06
62839SUPPL2020-05-06
62838SUPPL2020-05-06
62835SUPPL2020-05-06
62834SUPPL2020-05-06
61392SUPPL2019-12-23
61349SUPPL2019-12-19
61348SUPPL2019-12-19
55872ORIG2018-10-11
48827ORIG2017-06-26
48801SUPPL2017-06-22
48800SUPPL2017-06-22